Effect of increase in duration of aprepitant consumption from 3 to 6 days on the prevention of nausea and vomiting in women receiving combination of anthracycline/cyclophosphamide chemotherapy: A randomized, crossover, clinical trial

Ahvazi, Negah Chaabi; Hemati, Simin; Mohamadianpanah, Mohamad

doi:10.4103/2277-9175.168605

Cited by 2 publications

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Single nucleotide polymorphisms might influence chemotherapy induced nausea in women with breast cancer

Oliva

Nilsson

Andersson

et al. 2017

Clinical and Translational Radiation Oncology

View full text Add to dashboard Cite

BackgroundWomen receiving FEC (5 fluorouracil, epirubicin and cyclophosphamide) chemotherapy (CT) for breast cancer (BC) often experience side effects such as nausea and vomiting. Individual variations of side effects occur in patients despite similar cancer therapy. The purpose of this study was to investigate a possible genetic background as a predictor for individual variations in nausea induced by CT.Methods114 women were included in the study. All women received adjuvant CT for BC. Self-reported nausea and vomiting was recorded in a structured diary over ten days following treatment. Blood samples were collected before the treatment and used for the detection of 48 single nucleotide polymorphisms (SNPs) in 43 genes. SNPs from each individual woman were analyzed for their relation to the patient-reported frequency and intensity of nausea and vomiting.ResultsEighty-four percent (n = 96) of the women reported acute or delayed nausea or combined nausea and vomiting during the ten days following CT. Three out of the forty-eight SNPs in the following genes: FAS/CD95, RB1/LPAR6 and CCL2 were found to be associated with a risk of nausea.ConclusionSNPs in the FAS/CD95, RB1/LPAR6 and CCL2 genes were found to be associated with nausea among women treated with adjuvant FEC for BC. SNPs analysis is fast and cost effective and can be done prior to any cancer therapy. The association between individual SNPs and severe side effects from FEC may contribute to a more personalized care of patients with BC.

show abstract

Single nucleotide polymorphisms might influence chemotherapy induced nausea in women with breast cancer

Oliva

Nilsson

Andersson

et al. 2017

Clinical and Translational Radiation Oncology

View full text Add to dashboard Cite

show abstract

Prediction of side effects from anticancer treatment with the purpose of increasing quality of life

Oliva

2019

Linköping University Medical Dissertations

View full text Add to dashboard Cite

AbbreviationsABCA1 ATP-binding cassette transporter A member1 ANV Anticipatory Nausea and Vomiting ARSR Acute Radiation Skin Reactions ATM Ataxia telangiectasia mutated BC Breast cancer BRCA1 Breast cancer 1 BRCA2 Breast cancer 2 Casp 8 Caspase 8, apoptosis-related cysteine peptidase Casp 9 Caspase 9, apoptosis-related cysteine peptidase CCL2 Chemokine (C-C motif) ligand 2 CCL4 Chemokine (C-C motif) ligand 4 CCL5/RANTES Chemokine (C-C motif) ligand 5 CCND3 Cyclin D3 CDKN2A Cyclin-dependent kinase inhibitor 2A CI Confidence interval CINV Chemotherapy Induced Nausea and Vomiting CRP C-reactive protein CRF Case Report Form

show abstract

Effect of increase in duration of aprepitant consumption from 3 to 6 days on the prevention of nausea and vomiting in women receiving combination of anthracycline/cyclophosphamide chemotherapy: A randomized, crossover, clinical trial

Cited by 2 publications

References 27 publications

Single nucleotide polymorphisms might influence chemotherapy induced nausea in women with breast cancer

Single nucleotide polymorphisms might influence chemotherapy induced nausea in women with breast cancer

Prediction of side effects from anticancer treatment with the purpose of increasing quality of life

Contact Info

Product

Resources

About